Last Updated: August 2026
Published by: Saif Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Farhan Hossain, MBBS, MD (Oncology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from SFDA and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: inceptapharma.com, global.beaconpharma.com.bd, drugs.com, drugs.com, accessdata.fda.gov

Key Takeaways
- Sofosbuvir + Velpatasvir is a fixed-dose oral tablet combining an NS5B polymerase inhibitor and an NS5A inhibitor, approved for chronic hepatitis C virus genotype 1 through 6 infection in patients 18 years and older.
- The combination is available in 400 mg/100 mg and 200 mg/50 mg tablet strengths, and is used with ribavirin in cases of decompensated cirrhosis.
- We supply this therapy under the Bangladeshi-manufactured brand names Velpanex, Hopso-VL, Panovir 400, and Sofosvel, sourced from established manufacturers including Incepta Pharmaceuticals and Beacon Pharmaceuticals Ltd.
- A serious risk of therapy is hepatitis B virus reactivation in patients coinfected with HCV and HBV, which can lead to fulminant hepatitis, hepatic failure, or death.
- Drug interactions may occur with P-gp and CYP inducers such as rifampin, St. John’s wort, and carbamazepine, which can reduce therapeutic effectiveness.
- These Bangladeshi-manufactured brands are exported to Saudi Arabia through structured channels with full documentation, including Certificates of Analysis, MSDS, and commercial invoices, to support SFDA-aligned import requirements.
Sofosbuvir + Velpatasvir: Composition, Strength & Dosage Forms
Sofosbuvir + Velpatasvir is a fixed-dose combination antiviral belonging to the therapeutic class of Hepatitis C medications, specifically an HCV NS5B polymerase inhibitor combined with an NS5A inhibitor. This combination is formulated as an oral tablet intended for the treatment of chronic hepatitis C virus infection in adult patients.
The product is available in two strengths: a 400 mg/100 mg tablet and a 200 mg/50 mg tablet, allowing procurement flexibility depending on the clinical protocol specified by the prescribing physician. As a fixed-dose combination, each tablet contains both active moieties in a single unit for oral administration.
We supply this generic combination under the Bangladeshi-manufactured brand names Velpanex, Hopso-VL, Panovir 400, and Sofosvel. Panovir is marketed by Incepta Pharmaceuticals, while Sofosvel is marketed by Beacon Pharmaceuticals Ltd. — both established Bangladeshi pharmaceutical manufacturers with export-grade production standards.
No specific dose, regimen, or frequency information is provided here. Dosing must always be determined by the treating physician in accordance with the official prescribing information, taking into account the patient’s genotype, cirrhosis status, and treatment history. Procurement partners and healthcare providers sourcing sofosbuvir velpatasvir tablets 400mg 100mg or the 200 mg/50 mg strength should refer exclusively to approved prescribing documentation for administration guidance rather than generalized dosing assumptions.
This composition and strength information reflects publicly available prescribing data for the sofosbuvir and velpatasvir molecule combination as approved internationally. Our editorial and regulatory affairs team cross-references this content against manufacturer package inserts and international prescribing information to maintain factual accuracy for institutional buyers and healthcare procurement professionals.

Approved Indications and Mechanism of Action
Sofosbuvir + Velpatasvir is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection in patients 18 years of age and older without cirrhosis or with compensated cirrhosis. It is also approved for chronic HCV infection with decompensated cirrhosis, in which case it is used in combination with ribavirin. This broad genotype coverage makes the combination relevant across diverse HCV patient populations encountered in regulated markets.
This age threshold should be treated as consistent across all clinical and procurement documentation referencing this indication.
Mechanistically, the combination pairs two complementary modes of antiviral action. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor, interfering with the viral enzyme responsible for RNA replication. Velpatasvir is an NS5A inhibitor, targeting a distinct protein essential to viral assembly and replication. Together, these mechanisms provide pangenotypic antiviral activity. While efficacy in NS5A inhibitor-experienced patients has not been established for all HCV regimens, retreatment studies have demonstrated high efficacy for certain regimens such as glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir in patients who previously failed an NS5A inhibitor-containing regimen.
Clinicians evaluating genotype coverage and treatment-history considerations for individual patients should rely on the current, complete prescribing information rather than summarized content such as this article, which is intended to support procurement understanding rather than direct treatment decision-making.
Safety Information: Serious Risks and Drug Interactions
A serious risk associated with sofosbuvir velpatasvir therapy is hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV. This reactivation can present as fulminant hepatitis, hepatic failure, and, in severe cases, death. Screening for HBV coinfection and appropriate monitoring during and after treatment is a clinical consideration that healthcare providers must evaluate per prescribing information.
Drug interaction risk is another critical safety consideration. Sofosbuvir and velpatasvir are substrates of the drug transporters P-glycoprotein (P-gp) and BCRP, and velpatasvir is additionally transported by OATP1B1 and OATP1B3. The combination is also affected by pathways involving CYP2B6, CYP2C8, and CYP3A4. Inducers of P-gp and moderate-to-strong inducers of these CYP enzymes — such as rifampin, St. John’s wort, and carbamazepine — may decrease plasma concentrations of sofosbuvir and/or velpatasvir, reducing therapeutic effectiveness.
No dosage recommendation can be given for patients with severe renal impairment (eGFR ≤ 30 mL/min/1.73 m²) or with end-stage renal disease, due to higher exposures of the predominant sofosbuvir metabolite in these populations. Healthcare providers and institutional buyers should consult the full prescribing information and clinical judgment before initiating therapy in any patient with complex comorbidities or concomitant medication regimens.
This safety summary is compiled for procurement and institutional reference purposes and is not a substitute for full prescribing information, pharmacovigilance guidance, or individualized clinical assessment. Healthcare institutions should maintain direct access to current safety labeling for any patient-level decision-making.

Regulatory Status and Export Compliance for Saudi Arabia
Velpanex, Hopso-VL, Panovir 400, and Sofosvel are manufactured in Bangladesh by established pharmaceutical companies and are exported to Saudi Arabia to meet regulated market demand for HCV treatment options. These products are not manufactured locally in Saudi Arabia; all supply is conducted through structured export channels designed to align with the documentation expectations of the Saudi Food and Drug Authority (SFDA) for imported pharmaceuticals.
Export shipments are supported by complete documentation packages, including Certificates of Analysis (COA), Material Safety Data Sheets (MSDS), and commercial invoices, enabling buyers, distributors, and healthcare institutions to satisfy regulatory and customs requirements associated with named-patient or regulated-market pharmaceutical supply into Saudi Arabia.
The sofosbuvir and velpatasvir combination as a molecule has received international regulatory recognition, including FDA approval and European Commission approval, underscoring the established global clinical evidence base supporting this therapeutic combination. These international approvals reflect recognition of the active pharmaceutical ingredients’ safety and efficacy profile; they do not constitute an SFDA-specific approval claim for our supplied Bangladeshi brands, and buyers should independently verify current registration status for their intended use case.
Our regulatory affairs and export compliance team maintains direct working knowledge of documentation standards expected by Saudi customs and pharmaceutical import authorities, based on ongoing shipment experience into the region. We recommend that buyers confirm specific registration and import requirements with their own regulatory counsel or the SFDA directly prior to finalizing procurement, as import compliance requirements can be subject to change.
Wholesale, Export & Supply Capabilities
We provide bulk wholesale supply of Sofosbuvir + Velpatasvir tablets in both the 400 mg/100 mg and 200 mg/50 mg strengths, sourced directly from Bangladeshi manufacturers under Velpanex, Hopso-VL, Panovir 400, and Sofosvel brand lines. Our supply infrastructure is built to serve institutional buyers, distributors, and pharmacy networks operating across Saudi Arabia and the broader Gulf region.
Our export operations include full international shipping coordination and comprehensive documentation support — covering Certificates of Analysis, Material Safety Data Sheets, packing lists, and commercial invoices — to facilitate smooth customs clearance and regulatory review at the destination market.
We maintain consistent sourcing relationships with Bangladeshi manufacturers to support reliable, ongoing availability for buyers seeking dependable HCV treatment supply chains. Whether procurement volume needs are recurring institutional orders or one-time distributor shipments, our team is structured to accommodate varying order profiles. Contact us for availability and pricing specific to your procurement requirements, strength preference, and shipment destination within Saudi Arabia.
Our supply chain team draws on hands-on experience coordinating multi-shipment export relationships for hepatitis C therapies specifically, giving us practical familiarity with the batch traceability, cold-chain-independent handling, and documentation sequencing that institutional buyers in this therapeutic category typically require.

Why Choose Us as Your Bangladeshi Pharmaceutical Supplier
As a Bangladesh-based B2B pharmaceutical exporter, we specialize in sourcing and supplying quality-manufactured medications to regulated markets including Saudi Arabia. Our portfolio spans antiviral therapies for chronic hepatitis C, alongside broader chronic-disease treatment categories, giving institutional buyers a consolidated sourcing partner for diverse therapeutic needs.
We source exclusively from Bangladeshi pharmaceutical manufacturers, ensuring consistency in supply chain oversight, documentation standards, and quality traceability across every product we export. This focused sourcing model allows us to build deep manufacturer relationships and maintain reliable inventory visibility for our buyers.
The sofosbuvir and velpatasvir therapy class is globally recognized under brand names such as Epclusa, reflecting the broader international clinical adoption of this treatment approach. Our role is to connect Saudi Arabian buyers with the Bangladeshi-manufactured equivalents — Velpanex, Hopso-VL, Panovir 400, and Sofosvel — through compliant, well-documented export pathways tailored to regulated pharmaceutical trade requirements.
Our team’s authority in this space is built on direct, ongoing manufacturer relationships rather than intermediary sourcing, which allows us to verify batch documentation and production standards firsthand before products enter our export pipeline to Saudi Arabia and the wider Gulf region.
Related Antiviral Products We Supply
Beyond Sofosbuvir + Velpatasvir, our portfolio includes additional Bangladeshi-manufactured antiviral and hepatitis-related products designed to support comprehensive treatment sourcing for institutional buyers. Our therapeutic class coverage within hepatitis C management allows distributors and healthcare procurement teams to consolidate multiple product lines through a single, reliable export partner.
This breadth of portfolio reflects our commitment to serving diverse B2B buyer needs, from single-product orders to multi-brand institutional procurement across chronic hepatitis treatment categories. As our manufacturer relationships expand, we continue to evaluate additional antiviral offerings from Bangladeshi pharmaceutical companies to further strengthen our hepatitis C and related chronic-disease product range.
For buyers evaluating full-category sourcing options, we recommend contacting our team directly to discuss current product availability, manufacturer specifications, and export documentation support across our antiviral portfolio.
Frequently Asked Questions
What is Sofosbuvir + Velpatasvir used for?
Sofosbuvir + Velpatasvir is used to treat chronic hepatitis C virus infection across genotypes 1 through 6 in patients without cirrhosis or with compensated cirrhosis, and it is also used with ribavirin for patients with decompensated cirrhosis.
What medicines should not be taken with sofosbuvir and velpatasvir?
Medicines that induce P-glycoprotein or are moderate-to-strong inducers of CYP2B6, CYP2C8, or CYP3A4 can lower plasma levels of sofosbuvir and velpatasvir and reduce their effectiveness.
Examples mentioned include rifampin, St. John’s wort, and carbamazepine.
What are the serious side effects of this medication?
The most notable serious risk is hepatitis B virus reactivation in patients coinfected with HCV and HBV.
This reactivation can present as fulminant hepatitis, hepatic failure, and, in severe cases, death, so screening and monitoring for HBV coinfection is an important clinical consideration.
Who should not take Sofosbuvir + Velpatasvir?
Patients with severe renal impairment or end-stage renal disease do not have an established dosage recommendation due to higher exposure to a sofosbuvir metabolite in these populations.
Additionally, efficacy has not been established in patients whose previous treatment with an HCV NS5A inhibitor-containing regimen failed, so treatment decisions should always follow physician evaluation and official prescribing information.
Do you supply Sofosbuvir + Velpatasvir to buyers in Saudi Arabia?
Yes, we export Bangladeshi-manufactured Velpanex, Hopso-VL, Panovir 400, and Sofosvel to Saudi Arabia to meet regulated market demand for HCV treatment options.
Shipments are supported by complete documentation, including Certificates of Analysis, Material Safety Data Sheets, and commercial invoices, to assist with customs and regulatory review.
What strengths and order volumes are available for wholesale procurement?
We provide bulk wholesale supply in both 400 mg/100 mg and 200 mg/50 mg tablet strengths under our supplied brand lines.
Our supply structure accommodates both recurring institutional orders and one-time distributor shipments, and buyers can contact our team for availability specific to their procurement needs.
- 1. www.inceptapharma.com
- 2. global.beaconpharma.com.bd
- 3. www.drugs.com
- 4. www.drugs.com
- 5. www.accessdata.fda.gov
Access This Medicine Through Saif Pharma
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in August 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.